Connie Wu
YOU?
Author Swipe
View article: LINE-1 ORF1p expression occurs in clear cell ovarian carcinoma precursors and is a candidate blood biomarker
LINE-1 ORF1p expression occurs in clear cell ovarian carcinoma precursors and is a candidate blood biomarker Open
Long interspersed element 1 (LINE-1) retrotransposons are repetitive sequences that can move within the genome by an autonomous mechanism. To limit their mutagenic potential, benign cells restrict LINE-1 expression through molecular mechan…
View article: Supplementary Figure 3 from Ultrasensitive Detection of Circulating LINE-1 ORF1p as a Specific Multicancer Biomarker
Supplementary Figure 3 from Ultrasensitive Detection of Circulating LINE-1 ORF1p as a Specific Multicancer Biomarker Open
Circulating ORF1p levels in lung cancer patient cohort
View article: Supplementary Figure 10 from Ultrasensitive Detection of Circulating LINE-1 ORF1p as a Specific Multicancer Biomarker
Supplementary Figure 10 from Ultrasensitive Detection of Circulating LINE-1 ORF1p as a Specific Multicancer Biomarker Open
Representative SPR sensorgrams of ORF1 nanobodies.
View article: Supplementary Figure 8 from Ultrasensitive Detection of Circulating LINE-1 ORF1p as a Specific Multicancer Biomarker
Supplementary Figure 8 from Ultrasensitive Detection of Circulating LINE-1 ORF1p as a Specific Multicancer Biomarker Open
Circulating ORF1p (first generation Simoa assay) versus prostate-specific antigen (PSA).
View article: Supplementary Figure 28 from Ultrasensitive Detection of Circulating LINE-1 ORF1p as a Specific Multicancer Biomarker
Supplementary Figure 28 from Ultrasensitive Detection of Circulating LINE-1 ORF1p as a Specific Multicancer Biomarker Open
Kaplan-Meier Survival Analysis by Age and Sex.
View article: Supplementary Figure 29 from Ultrasensitive Detection of Circulating LINE-1 ORF1p as a Specific Multicancer Biomarker
Supplementary Figure 29 from Ultrasensitive Detection of Circulating LINE-1 ORF1p as a Specific Multicancer Biomarker Open
Schoenfeld Tests and Residuals.
View article: Supplementary Figure 2 from Ultrasensitive Detection of Circulating LINE-1 ORF1p as a Specific Multicancer Biomarker
Supplementary Figure 2 from Ultrasensitive Detection of Circulating LINE-1 ORF1p as a Specific Multicancer Biomarker Open
Circulating ORF1p levels in eight stage I ovarian cancer patients
View article: Supplementary Figure 15 from Ultrasensitive Detection of Circulating LINE-1 ORF1p as a Specific Multicancer Biomarker
Supplementary Figure 15 from Ultrasensitive Detection of Circulating LINE-1 ORF1p as a Specific Multicancer Biomarker Open
Validation of monoclonal antibodies by western blotting.
View article: Supplementary Figure 21 from Ultrasensitive Detection of Circulating LINE-1 ORF1p as a Specific Multicancer Biomarker
Supplementary Figure 21 from Ultrasensitive Detection of Circulating LINE-1 ORF1p as a Specific Multicancer Biomarker Open
(obtained from Drapkin Lab at the University of Pennsylvania).Circulating CA125 and HE4 levels, as measured by Simoa, in ovarian cancer patient cohort.
View article: Supplementary Figure 9 from Ultrasensitive Detection of Circulating LINE-1 ORF1p as a Specific Multicancer Biomarker
Supplementary Figure 9 from Ultrasensitive Detection of Circulating LINE-1 ORF1p as a Specific Multicancer Biomarker Open
Nanobody generation
View article: Supplementary Figure 25 from Ultrasensitive Detection of Circulating LINE-1 ORF1p as a Specific Multicancer Biomarker
Supplementary Figure 25 from Ultrasensitive Detection of Circulating LINE-1 ORF1p as a Specific Multicancer Biomarker Open
Second round of screening of newly developed “3rd generation” assays using dimeric nanobody detectors.
View article: Supplementary Figure 17 from Ultrasensitive Detection of Circulating LINE-1 ORF1p as a Specific Multicancer Biomarker
Supplementary Figure 17 from Ultrasensitive Detection of Circulating LINE-1 ORF1p as a Specific Multicancer Biomarker Open
First round of screening of newly developed monoclonal antibody and dimeric nanobody reagent pairs in patient plasma.
View article: Supplementary Figure 24 from Ultrasensitive Detection of Circulating LINE-1 ORF1p as a Specific Multicancer Biomarker
Supplementary Figure 24 from Ultrasensitive Detection of Circulating LINE-1 ORF1p as a Specific Multicancer Biomarker Open
Calibration curves for “3rd Generation” Simoa assays.
View article: Supplementary Figure 14 from Ultrasensitive Detection of Circulating LINE-1 ORF1p as a Specific Multicancer Biomarker
Supplementary Figure 14 from Ultrasensitive Detection of Circulating LINE-1 ORF1p as a Specific Multicancer Biomarker Open
Representative SPR sensorgrams of ORF1 “3rd Gen.” nanobody multimers with “5xCys Tail.
View article: Supplementary Figure 19 from Ultrasensitive Detection of Circulating LINE-1 ORF1p as a Specific Multicancer Biomarker
Supplementary Figure 19 from Ultrasensitive Detection of Circulating LINE-1 ORF1p as a Specific Multicancer Biomarker Open
Assay validation for second-generation ORF1p Simoa assays.
View article: Supplementary Figure 10 from Ultrasensitive Detection of Circulating LINE-1 ORF1p as a Specific Multicancer Biomarker
Supplementary Figure 10 from Ultrasensitive Detection of Circulating LINE-1 ORF1p as a Specific Multicancer Biomarker Open
Representative SPR sensorgrams of ORF1 nanobodies.
View article: Supplementary Figure 4 from Ultrasensitive Detection of Circulating LINE-1 ORF1p as a Specific Multicancer Biomarker
Supplementary Figure 4 from Ultrasensitive Detection of Circulating LINE-1 ORF1p as a Specific Multicancer Biomarker Open
Circulating ORF1p levels in patients with IPMN
View article: Supplementary Figure 6 from Ultrasensitive Detection of Circulating LINE-1 ORF1p as a Specific Multicancer Biomarker
Supplementary Figure 6 from Ultrasensitive Detection of Circulating LINE-1 ORF1p as a Specific Multicancer Biomarker Open
Analysis of circulating ORF1p levels in extracellular vesicles (EVs) fractions.
View article: Supplementary Data 1 from Ultrasensitive Detection of Circulating LINE-1 ORF1p as a Specific Multicancer Biomarker
Supplementary Data 1 from Ultrasensitive Detection of Circulating LINE-1 ORF1p as a Specific Multicancer Biomarker Open
De-identified patient information for survival analysis.
View article: Supplementary Figure 22 from Ultrasensitive Detection of Circulating LINE-1 ORF1p as a Specific Multicancer Biomarker
Supplementary Figure 22 from Ultrasensitive Detection of Circulating LINE-1 ORF1p as a Specific Multicancer Biomarker Open
Circulating ORF1p levels in breast cancer patients.
View article: Supplementary Figure 14 from Ultrasensitive Detection of Circulating LINE-1 ORF1p as a Specific Multicancer Biomarker
Supplementary Figure 14 from Ultrasensitive Detection of Circulating LINE-1 ORF1p as a Specific Multicancer Biomarker Open
Representative SPR sensorgrams of ORF1 “3rd Gen.” nanobody multimers with “5xCys Tail.
View article: Supplementary Figure 6 from Ultrasensitive Detection of Circulating LINE-1 ORF1p as a Specific Multicancer Biomarker
Supplementary Figure 6 from Ultrasensitive Detection of Circulating LINE-1 ORF1p as a Specific Multicancer Biomarker Open
Analysis of circulating ORF1p levels in extracellular vesicles (EVs) fractions.
View article: Supplementary Figure 24 from Ultrasensitive Detection of Circulating LINE-1 ORF1p as a Specific Multicancer Biomarker
Supplementary Figure 24 from Ultrasensitive Detection of Circulating LINE-1 ORF1p as a Specific Multicancer Biomarker Open
Calibration curves for “3rd Generation” Simoa assays.
View article: Supplementary Figure 27 from Ultrasensitive Detection of Circulating LINE-1 ORF1p as a Specific Multicancer Biomarker
Supplementary Figure 27 from Ultrasensitive Detection of Circulating LINE-1 ORF1p as a Specific Multicancer Biomarker Open
Kaplan-Meier Survival Analysis by ORF1p.
View article: Supplementary Figure 4 from Ultrasensitive Detection of Circulating LINE-1 ORF1p as a Specific Multicancer Biomarker
Supplementary Figure 4 from Ultrasensitive Detection of Circulating LINE-1 ORF1p as a Specific Multicancer Biomarker Open
Circulating ORF1p levels in patients with IPMN
View article: Supplementary Figure 2 from Ultrasensitive Detection of Circulating LINE-1 ORF1p as a Specific Multicancer Biomarker
Supplementary Figure 2 from Ultrasensitive Detection of Circulating LINE-1 ORF1p as a Specific Multicancer Biomarker Open
Circulating ORF1p levels in eight stage I ovarian cancer patients
View article: Supplementary Figure 13 from Ultrasensitive Detection of Circulating LINE-1 ORF1p as a Specific Multicancer Biomarker
Supplementary Figure 13 from Ultrasensitive Detection of Circulating LINE-1 ORF1p as a Specific Multicancer Biomarker Open
Representative SPR sensorgrams of ORF1 monoclonal antibodies and “2nd Gen.” nanobody multimers.
View article: Supplementary Figure 9 from Ultrasensitive Detection of Circulating LINE-1 ORF1p as a Specific Multicancer Biomarker
Supplementary Figure 9 from Ultrasensitive Detection of Circulating LINE-1 ORF1p as a Specific Multicancer Biomarker Open
Nanobody generation
View article: Supplementary Figure 26 from Ultrasensitive Detection of Circulating LINE-1 ORF1p as a Specific Multicancer Biomarker
Supplementary Figure 26 from Ultrasensitive Detection of Circulating LINE-1 ORF1p as a Specific Multicancer Biomarker Open
Calibration curve for the large-volume (500 µL) MOSAIC assay.
View article: Supplementary Figure 15 from Ultrasensitive Detection of Circulating LINE-1 ORF1p as a Specific Multicancer Biomarker
Supplementary Figure 15 from Ultrasensitive Detection of Circulating LINE-1 ORF1p as a Specific Multicancer Biomarker Open
Validation of monoclonal antibodies by western blotting.